200 related articles for article (PubMed ID: 16563772)
1. Antisense oligonucleotides: efficient synthesis of 2'-O-methoxyethyl phosphorothioate oligonucleotides using 4,5-dicyanoimidazole. Are these oligonucleotides comparable to those synthesized using 1H-tetrazole as coupling activator?
Wang Z; Siwkowski A; Lima WF; Olsen P; Ravikumar VT
Bioorg Med Chem; 2006 Jul; 14(14):5049-60. PubMed ID: 16563772
[TBL] [Abstract][Full Text] [Related]
2. A novel universal linker for efficient synthesis of phosphorothioate oligonucleotides.
Wang Z; Olsen P; Ravikumar VT
Nucleosides Nucleotides Nucleic Acids; 2007; 26(3):259-69. PubMed ID: 17454735
[TBL] [Abstract][Full Text] [Related]
3. Efficient activation of nucleoside phosphoramidites with 4,5-dicyanoimidazole during oligonucleotide synthesis.
Vargeese C; Carter J; Yegge J; Krivjansky S; Settle A; Kropp E; Peterson K; Pieken W
Nucleic Acids Res; 1998 Feb; 26(4):1046-50. PubMed ID: 9461466
[TBL] [Abstract][Full Text] [Related]
4. Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.
Seth PP; Siwkowski A; Allerson CR; Vasquez G; Lee S; Prakash TP; Wancewicz EV; Witchell D; Swayze EE
J Med Chem; 2009 Jan; 52(1):10-3. PubMed ID: 19086780
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of high quality phosphorothioate oligonucleotides as antisense drugs. Use of I-linker in the elimination of 3'-terminal phosphorothioate monoesters.
Ravikumar VT; Kumar RK; Capaldi DC; Cole DL
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1421-5. PubMed ID: 14565433
[TBL] [Abstract][Full Text] [Related]
6. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
[TBL] [Abstract][Full Text] [Related]
7. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
8. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
Henry SP; Geary RS; Yu R; Levin AA
Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
[TBL] [Abstract][Full Text] [Related]
12. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
Crooke RM
Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
[TBL] [Abstract][Full Text] [Related]
13. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of chimeric oligonucleotides containing phosphodiester, phosphorothioate, and phosphoramidate linkages.
Maier MA; Guzaev AP; Manoharan M
Org Lett; 2000 Jun; 2(13):1819-22. PubMed ID: 10891166
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and cellular activity of stereochemically-pure 2'-O-(2-methoxyethyl)-phosphorothioate oligonucleotides.
Li M; Lightfoot HL; Halloy F; Malinowska AL; Berk C; Behera A; Schümperli D; Hall J
Chem Commun (Camb); 2017 Jan; 53(3):541-544. PubMed ID: 27966701
[TBL] [Abstract][Full Text] [Related]
16. Electrospray mass spectrometry for the characterization of the purity of natural and modified oligodeoxynucleotides.
Deroussent A; Le Caer JP; Rossier J; Gouyette A
Rapid Commun Mass Spectrom; 1995; 9(1):1-4. PubMed ID: 7888705
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.
Shen L; Siwkowski A; Wancewicz EV; Lesnik E; Butler M; Witchell D; Vasquez G; Ross B; Acevedo O; Inamati G; Sasmor H; Manoharan M; Monia BP
Antisense Nucleic Acid Drug Dev; 2003; 13(3):129-42. PubMed ID: 12954113
[TBL] [Abstract][Full Text] [Related]
18. The synthesis of therapeutic locked nucleos(t)ides.
Zhou C; Chattopadhyaya J
Curr Opin Drug Discov Devel; 2009 Nov; 12(6):876-98. PubMed ID: 19894196
[TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism of 2'-ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry.
Kim J; El Zahar NM; Bartlett MG
Biomed Chromatogr; 2020 Jul; 34(7):e4839. PubMed ID: 32246854
[TBL] [Abstract][Full Text] [Related]
20. Alpha-hydroxybenzylphosphonate modified oligonucleotides: synthesis, properties, and a novel route via monomer building blocks.
Hohlfeld A; Meier C
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1123-5. PubMed ID: 14565360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
